Concert Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Concert Pharma (CNCE) Reports Q1 Loss of $0.93/Share
May 2, 2019 7:44 AM EDTConcert Pharma (NASDAQ: CNCE) reported Q1 EPS of ($0.93), versus ($0.19) reported last year. Revenue for the quarter came in at $1 million, versus $10.48 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More